Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293357 | 0.88 | MEN1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4292291 | 0.87 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2HSD17B10CA1 | |
| SCHEMBL4287492 | 0.86 | MEN1 (0.41) | MEN1KMT2AHSD17B10CA1CA2 | |
| SCHEMBL13704124 | 0.86 | MEN1 (0.39) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4296392 | 0.86 | MEN1 (0.42) | MEN1KMT2ACA1CA2CA7 | |
| SCHEMBL4300577 | 0.85 | NTRK1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4296729 | 0.85 | MEN1 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4297017 | 0.84 | KMT2A (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4293360 | 0.83 | MEN1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4287067 | 0.83 | MEN1 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | MEN1 4829/4885KMT2A 1440/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.